October 16, 2018
RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced demonstrations of its Senhance™ Surgical System at the American College of Surgeons (ACS) Clinical Congress 2018 at the Boston Convention & Visitors Center in Boston, MA, October 21 – 25.
Surgeons, Hospital Administrators and related staff are invited to experience Senhance Surgery during the Company’s daily demonstrations located at the TransEnterix booth #577, from Monday, October 22 – Wednesday, October 24 from 10:30 a.m. – 11:30 a.m. ET. Participants will witness how digital laparoscopy is redefining minimally invasive surgery through meaningful technology, designed to compete in today’s value-based healthcare landscape. To schedule a demonstration in advance, visit transenterix.com/events.
“Digital laparoscopy with the Senhance System provides a digitized interface between the surgeon and patient, giving surgeons improved control, comfort, clinical intelligence and confidence when performing a wide variety of procedures with the goal of delivering superior value to more patients,” said TransEnterix Chief Commercial Officer, Eric Smith. “We look forward to attending ACS and demonstrating how digital laparoscopy with the Senhance is ushering in a new era of minimally invasive surgery.”
The Senhance Surgical System received U.S. FDA clearance in October 2017 and represents the first robotic surgery platform to enter the U.S. market since 2000. It is the only digital laparoscopic platform available that offers reusable instruments to help keep costs down, as well as haptic feedback, which allows surgeons to experience and sense pressure/tension with alerts if pressure threshold is reached – an added layer of security. The System combines much-needed technological advances with economic advantages and represents a fundamental change in the approach to minimally invasive surgery.
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.
Forward Looking Statements
This press release includes statements relating to the Senhance Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance System will usher in a new era of minimally invasive surgery. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 8, 2018, and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.